Comparative analysis of phase III ASCENT-03 and TROPION-Breast02 trial cohorts suggests first-line TROP2-targeted antibody–drug conjugates improve progression-free survival compared with standard chemotherapy in metastatic triple-negative breast cancer patients ineligible for immunotherapy. The dataset frames consistent PFS benefit across the immunotherapy-ineligible subgroup comparisons. The analysis reinforces the continuing shift toward tumor-antigen selection in ADC development, where clinical benefit appears to depend on target engagement and patient eligibility criteria rather than solely on histology. No additional survival metrics or safety rates were included in the provided content.
Get the Daily Brief